Shares in Mylan (NDSQ:MYL) rose slightly today after the pharmaceutical giant missed expectations on Wall Street with its 3rd-quarter results.
The Canonsburg, Pa.-based company posted a net loss of -$119.8 million, or -23¢ per share, on sales of $3.06 billion for the 3 months ended Sept. 30, for a bottom-line slide of -3% on sales growth of 14.2% compared with the same period last year.
Get the full story at our sister site, Drug Delivery Business News.
The post Mylan misses on top & bottom lines, citing $465 million settlement appeared first on MassDevice.
from MassDevice http://www.massdevice.com/mylan-misses-top-bottom-lines-citing-465-million-settlement/
Cap comentari:
Publica un comentari a l'entrada